Unknown Manufacturer
REP8839 is a novel methionyl-tRNA synthetase (MetS) inhibitor being developed by Replidyne (GlaxoSmithKline licensed REP8839 to Replidyne in June of 2003).
REP8839 is a novel methionyl-tRNA synthetase (MetS) inhibitor being developed by Replidyne (GlaxoSmithKline licensed REP8839 to Replidyne in June of 2003).
REP8839 exerts its antibacterial activity through specific inhibition of MetS, a novel target.
For the treatment of bacterial infections caused by susceptible microorganisms (Staphylococcus aureus, including methicillin-resistant S. aureus (MRSA), and Streptococcus pyogenes).
One entry per invention. Patent families filed in the US, EP, WO and CN offices.
